Press Release
PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Presentation at the American College of Cardiology’s 68th Annual Scientific Session
Presentation details are as follows:
Title: First Randomized Human Experience with a Ticagrelor Reversal Agent
Session: Late-Breaking Clinical Trials, Featured Clinical Research II: Interventional
Session Number: 408
Date / Time:
Location:
Presenter:
Additional information on the scientific session can be found on the ACC website: https://accscientificsession.acc.org/.
About PB2452
PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, or Fab fragment, designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations. In clinical and preclinical studies, PB2452 achieved immediate and sustained reversal of ticagrelor’s antiplatelet activity, thereby providing a potential life-saving therapeutic benefit by increasing the safety of ticagrelor, which like all other antiplatelet drugs, has an increased risk of bleeding. There are currently no approved reversal agents for ticagrelor or any other antiplatelet drugs.
About PhaseBio
PhaseBio is located in
Investor Contact:
Chief Financial Officer
(610) 981-6506
john.sharp@phasebio.com
Media Contact:
6 Degrees
(215) 313-5638
shall@6degreespr.com
Source: PhaseBio Pharmaceuticals, Inc.